MVM Life Science Partners
MVM Life Science Partners is a venture capital firm specializing in investments in start-up, early stage, mid venture, late venture.
Business Model:
Revenue: $6.5M
Employees: 2-10
Rankings
Industries / Tags:
Detailed MVM Life Science Partners Information
Geographic Data
Address: 6 Henrietta Street
City: London
State: england
Zip: WC2E 8PU
Country: GB
Financial Info
Stage:
Raised Last:
$0
Raised Total:$1B
Social
Linkedin
Crunchbase
Metrics
3,548,468Website Global Rank
3,890Website Monthly Traffic
Twitter Followers
Description
MVM was founded in 1997 and manages four funds totalling more than US$700 million. MVM has invested in biopharmaceuticals, diagnostics, drug delivery, gene therapy, healthcare services, medical devices, OTC medicines, research tools and vaccines.
Contact Phone:
+12075577500
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 2/2009 | Heptares Therapeutics | Series A | 30M |
| 9/2017 | Cheetah Medical | Series C | 0 |
| 2/2014 | Cheetah Medical | Series C | 0 |
| 4/2010 | Cheetah Medical | Series B | 20M |
| 10/2017 | VitalConnect | Series C | 38M |
| 12/2016 | Providence Medical Technology | Series E | 10.5M |
| 1/2013 | eZono | Venture Round | 10M |
| 9/2018 | Providence Medical Technology | Equity | 25M |
| 12/2021 | Vero Biotech | Series E | 100M |
| 4/2014 | Wilson Therapeutics | Series B | 40M |
| 1/2002 | BioXell | Series A | 19.7M |
| 9/2003 | Xention | Venture Round | 6.4M |
| 6/2017 | Vertos Medical | Venture Round | 0 |
| 5/2014 | Tarsa Therapeutics | Series B | 0 |
| 4/2003 | Oxxon Therapeutics | Venture Round | 0 |
| 7/2010 | Cara Therapeutics | Series D | 0 |
| 11/2020 | GT Medical Technologies | Series B | 16M |
| 8/2020 | Paragon 28 | Series B | - |
| 1/2010 | Tarsa Therapeutics | Series A | 24M |
| 11/2006 | Cara Therapeutics | Series C | 24M |
| 6/2017 | Zipline Medical | Series E | 12M |
| 5/2005 | Asstrodyne TDI | Series C | 26.4M |
| 6/2013 | Horizon Discovery | Venture Round | 10.6M |
| 10/2022 | Ossio | Series C | 38.5M |
| 2/2022 | Nalu Medical | Venture Round | 0 |
| 6/2014 | Vascular Pathways | Debt Financing | 0 |
| 4/2020 | MDxHealth | Post-IPO Equity | 0 |
| 6/2006 | Aegerion Pharmaceuticals | Series A | 22.5M |
| 3/2006 | BioXell | Series C | 12.7M |
| 6/2009 | Clavis Pharma | Post-IPO Equity | 20M |
| 7/2011 | AccuVein | Series B | 22.5M |
| 2/2002 | Avantium | Venture Round | 0 |
| 3/2004 | Momenta Pharmaceuticals | Series C | 20.5M |
| 3/2012 | Tarsa Therapeutics | Series B | 28M |
| 7/2011 | Vantia | Series B | 6.5M |
| 10/2004 | BioXell | Series C | 29M |
| 11/2010 | Vascular Pathways | Series B | 0 |
| 1/2016 | Biotheranostics | Venture Round | 32M |
| 4/2020 | SkyCell | Venture Round | 0 |
| 3/2009 | BioVex | Venture Round | 40M |
| 3/2023 | GT Medical Technologies | Series C | 0 |
| 4/2011 | Lombard Medical plc | Post-IPO Equity | 41.5M |
| 4/2015 | Onbone | Venture Round | 0 |
| 8/2007 | Heptares Therapeutics | Seed Round | - |
| 6/2007 | Serentis | Series A | 20.5M |
| 9/2021 | INBRACE | Series D | 0 |
| 4/2013 | Cheetah Medical | Venture Round | 14.5M |
| 1/2016 | Zipline Medical | Series D | 19M |
| 6/2007 | PregLem | Series A | 26M |
| 9/2011 | Horizon Discovery | Series C | 17.9M |
| 8/2008 | Serentis | Series A | 10.1M |
| 5/2003 | Momenta Pharmaceuticals | Series B | 19M |
| 11/2014 | AmbioPharm | Venture Round | 24M |
| 9/2022 | Neurolens | Venture Round | 67.6M |
| 12/2007 | PregLem | Series B | 32.2M |
| 6/2018 | Zipline Medical | Growth | 9M |
| 3/2021 | eXmoor Pharma | Venture Round | 16.8M |
| 8/2011 | Beacon Endoscopic | Venture Round | 8M |
| 5/2023 | eXmoor Pharma | Series A | 35M |
| 4/2004 | Evotec Neurosciences | Series A | 30.5M |
| 10/2010 | SOLX | Venture Round | 3.7M |
| 7/2001 | De Novo Pharmaceuticals | Series B | 0 |
| 11/2011 | Patient Connect | Series A | - |
| 2/2022 | Nalu Medical | Venture Round | 0 |
| 12/2021 | Vero Biotech | Series E | 0 |
| 9/2021 | INBRACE | Series D | 0 |
| 3/2021 | eXmoor Pharma | Venture Round | 0 |
| 11/2020 | GT Medical Technologies | Series B | 0 |
| 8/2020 | Paragon 28 | Series B | - |
| 4/2020 | SkyCell | Venture Round | 0 |
| 4/2020 | MDxHealth | Post-IPO Equity | 0 |
| 9/2018 | Providence Medical Technology | Venture Round | 0 |
| 6/2018 | Zipline Medical | Series F | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
